Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Toosendanin** is a naturally occurring tetracyclic triterpenoid compound extracted from the bark and fruits of *Melia toosendan* (Sieb et Zucc), a medicinal plant used in traditional Chinese medicine[1][2][5]. It is primarily recognized for its use as an ascaricide (anti-parasitic agent)[3][5], agricultural insecticide[1][2][5], and has demonstrated analgesic, anti-inflammatory, antibotulinum, and anticancer activities in preclinical settings[1][3][4][5][6]. Toosendanin acts as a selective presynaptic blocker, interfering with neurotransmitter release by initially facilitating and then depressing synaptic transmission, ultimately blocking neuro-muscular and central synapse activity[1][5]. It can also inhibit the growth and induce apoptosis of various tumor cell lines—including glioma, osteosarcoma, colorectal, liver, breast, and ovarian cancers—via multiple mechanisms involving suppression of PI3K/Akt/mTOR and STAT3 signaling, mitochondrial apoptotic pathways, and V-ATPase inhibition[3][4][6][7]. It has significant antibotulismic effects by preventing botulinum neurotoxin from accessing its SNARE protein substrate[1][5]. Its anti-inflammatory effects are related to modulation of M1 macrophage polarization, NLRP3 inflammasome activity, and Nrf2/HO-1 signaling[2]. Research also points to its effect on potassium channels, facilitation of calcium influx via L-type calcium channels, and intracellular calcium overload[1][5]. No approved pharmaceutical use in humans is reported; use is limited to agricultural and experimental research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on toosendanin.